Exact Sciences Corporation
NASDAQ•EXAS
執行長: Mr. Kevin T. Conroy J.D.
板塊: Healthcare
行業: Medical - Diagnostics & Research
上市日期: 2001-02-01
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
聯絡資訊
市值
$19.72B
本益比 (TTM)
-94.3
20.4
股息率
--
52周最高
$103.67
52周最低
$38.81
52周範圍
排名62Top 92.6%
1.9
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
疲弱 • 1.9 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025
財務儀表板
Q4 2025 數據
營業收入
$878.38M+0.00%
近4季度走勢
每股收益
-$0.45+0.00%
近4季度走勢
自由現金流
$120.45M+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Total Revenue Grew 17.7% Total revenue reached $3.25B USD in 2025, driven by 20.2% growth in Screening revenue segment.
Net Loss Significantly Narrowed Net loss reduced to $207.9M USD in 2025, a substantial improvement from $1.03B USD loss last year.
Operating Cash Flow Improved Cash provided by operating activities was $491.4M USD, reflecting a $280.9M USD improvement over 2024.
Abbott Merger Agreement Signed Entered Merger Agreement with Abbott for $105.00 cash per share; expected consummation in Q2 2026.
關注風險
Merger Execution Uncertainty Failure or delay in closing the Abbott Merger could materially affect operations and common stock price.
Dependence on Product Success Success heavily relies on commercialization of Screening and Precision Oncology tests in development pipeline.
Regulatory and Reimbursement Risks Uncertainty exists related to healthcare reform, pricing, coverage, and maintaining adequate reimbursement rates.
Need for Additional Capital Additional capital may be required to fully fund strategic plan; financing availability or terms are uncertain.
未來展望
Productivity Plan Implementation Implementing multi-year productivity plan targeting over $150M USD in expected annual savings by 2026.
Pipeline Development Investment Expect continued significant investment in R&D to enhance current products and advance pipeline offerings.
Next-Generation MRD Test Launch Plan to introduce next-generation Oncodetect MRD test leveraging MAESTRO technology in 2026.
International Expansion Exploration Exploring opportunities to make Cologuard and Cancerguard tests available outside the U.S. market soon.
同行對比
營業收入 (TTM)
$14.30B
$11.24B
$8.10B
毛利率 (最新季度)
96.1%
90.0%
89.9%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| ROIV | $21.27B | -25.6 | -18.3% | 4.0% |
| EXAS | $19.72B | -94.3 | -8.5% | 43.0% |
| ILMN | $19.61B | 23.1 | 34.9% | 38.4% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
7.5%
穩定增長
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
100%
現金流表現優異
深度研究
下次財報:2026年4月29日
每股收益:-
|營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料